Blood-based detection of actionable alterations from NCI-MATCH patients with no tissue results.
Robin Harrington(Frederick National Laboratory for Cancer Research), Chris Karlovich(Clovis Oncology (United States)), Rini Pauly(Frederick National Laboratory for Cancer Research), Jennifer S. LoCoco(Illumina (United States)), Traci Pawlowski(Illumina (United States)), Lisa M. McShane(National Cancer Institute), Amanda Peach(Frederick National Laboratory for Cancer Research), James H. Doroshow(National Cancer Institute), Alice P. Chen(National Institutes of Health), Shahanawaz Jiwani(Frederick National Laboratory for Cancer Research), Phillip G. Febbo(Veracyte (United States)), Biswajit Das(Frederick National Laboratory for Cancer Research), James V. Tricoli(National Cancer Institute), Naoko Takebe(National Institutes of Health), D. A. HOWELL(Frederick National Laboratory for Cancer Research), Li Chen(Harvard University), Jennifer Lee(The Catholic University of Korea Seoul St. Mary's Hospital), Paul M. Williams(Frederick National Laboratory for Cancer Research), Ting-Chia Chang(Frederick National Laboratory for Cancer Research)
Cited by 0
Related Papers
Gene expression correlates of clinical prostate cancer behavior
|Cancer Cell|2002|2.5k
mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways
|Nature Medicine|2004|956
Changes in circulating microRNA levels associated with prostate cancer
|British Journal of Cancer|2012|717
Rociletinib in <i>EGFR</i>-Mutated Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2015|664